✦ LIBER ✦

Abstract No. 358: Safety and tolerability of two dosing regimens of sorafenib in combination with locoregional therapy in patients with hepatocellular carcinoma

✍ Scribed by Freed, R.; Min, J.; Malik, S.B.; Moshfegh, A.; Vatakencherry, G.G.

Book ID: 123354144
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 56 KB
Volume: 23
Category: Article
ISSN: 1051-0443
DOI: 10.1016/j.jvir.2011.12.477

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Abstract No. 357: Safety of Combination

Abstract No. 357: Safety of Combination Sorafenib with Locoregional Therapy in Patients with Hepatocellular Carcinoma and Cirrhosis

✍ Shum, D.J.; Fong, C. Lim; Vatakencherry, G. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Safety and tolerance of sorafenib in Jap

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

✍ Sadahisa Ogasawara; Fumihiko Kanai; Shuntaro Obi; Shinpei Sato; Taketo Yamaguchi 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 182 KB

Safety and efficacy of locoregional ther

Safety and efficacy of locoregional therapy for hepatocellular carcinoma in patients with indwelling TIPS

✍ Chewning, R.H.; Kogut, M.; Kwan, S.W.; Monsky, W.L.; Valji, K.; Bhattacharya, R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase 2 Study of Combined Sorafenib and

Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma

✍ Chen, Shang-Wen; Lin, Li-Ching; Kuo, Yu-Cheng; Liang, Ji-An; Kuo, Chia-Chun; Chi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 489 KB

Meta-analysis of the safety and tolerabi

Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety

✍ John J. Sramek; Walter W. Hong; Suha Hamid; Barbara Nape; Neal R. Cutler 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

Buspirone is an azapirone with 5-HT 1A partial agonist activity which has demonstrated efficacy in the treatment of generalized anxiety disorder, commonly referred to as persistent anxiety. In this meta-analysis report, safety results from two studies comparing buspirone 15 mg twice daily (BID) with

A phase I dose-escalation study to evalu

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

✍ Desar, I M E; Timmer-Bonte, J N H; Burger, D M; van der Graaf, W T A; van Herpen 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 349 KB